In this context, the recent observation that PCSK9 inhibition/silencing in vivo enhances the levels of MHC-I via its PCSK9-induced degradation in endosomes/lysosomes [19] would suggest that this clinically safe treatment, though very effective in reducing hypercholesterolemia [117] and in cancer/metastasis treatments [19], may actually also enhance the contributions of the immune response to viral disease severity by exacerbating the LASV-induced inflammatory response, which represents a major hurdle in vaccine development against viral infections [118]. Here, PCSK9 is linked to Hypercholesterolemia.